Conversion from sustained release carbidopa/levodopa to Stalevo® in Parkinson's disease patients

被引：0

|

作者：

Pahwa, R

Lyons, KE

机构：

来源：

MOVEMENT DISORDERS | 2005年 / 20卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P237

引用

收藏

页码：S71 / S71

页数：1

相关论文

共 50 条

[1] Conversion from sustained release carbidopa/levodopa to carbidopa/levodopa/entacapone (Stalevo) in Parkinson disease patients
Lyons, KE
Pahwa, R
CLINICAL NEUROPHARMACOLOGY, 2006, 29 (02) : 73 - 76
[2] Early morning akinesia in Parkinson's disease: Effect of standard carbidopa levodopa and sustained-release carbidopa levodopa
Pahwa, R
Lyons, K
McGuire, D
Dubinsky, R
Hubble, JP
Koller, WC
NEUROLOGY, 1996, 46 (04) : 1059 - 1062
[3] Stalevo (levodopa/carbidopa/entacapon) - a new generation drug in the treatment of Parkinson's disease
Fedorova, N. V.
Levin, O. S.
Smolentseva, I. G.
Kulua, T. K.
ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2006, 106 (09) : 39 - 46
[4] Switch from levodopa/carbidopa to the corresponding Stalevo dosage improves motor symptoms and elevates levodopa plasma levels in patients with Parkinson's disease
Müller, T
Erdmann, C
Muhlack, S
Bremen, D
Przuntek, H
Woitalla, D
MOVEMENT DISORDERS, 2005, 20 : S46 - S46
[5] Determining the benefit of levodopa/carbidopa/entacapone (Stalevo®) on the pharmacokinetic profile of levodopa:: a randomized, crossover, multicentre study in patients with Parkinson's disease
Kaakola, S.
Ellmen, J.
Marttila, R.
Kaasinen, V.
Hartikainen, P.
Lyytinen, J.
Hanninen, J.
Korpela, K.
Kuoppamaki, M.
PARKINSONISM & RELATED DISORDERS, 2007, 13 : S100 - S100
[6] Determining the benefit of levodopa/carbidopa/entacapone (Stalevo®) on the pharmacokinetic profile of levodopa:: a randomized, crossover, multicentre study in patients with Parkinson's disease
Marttila, R.
Kaasinen, V.
Hartikainen, P.
Lyytinen, J.
Kaakkola, S.
Hanninen, J.
Korpela, K.
Laapas, K.
Kuoppamaki, M.
Ellmen, J.
EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 : 115 - 115
[7] Determining the benefit of levodopa/carbidopa/entacapone (Stalevo®) on the pharmacokinetic profile of levodopa:: A randomized, crossover, multicenter study in patients with Parkinson's disease
Marttila, R.
Kaasinen, V.
Hartikainen, P.
Lyytinen, J.
Kaakkola, S.
Haenninen, J.
Korpela, K.
Laapas, K.
Kuoppamaeki, M.
Ellmen, J.
MOVEMENT DISORDERS, 2008, 23 (01) : S213 - S213
[8] Conversion of advanced Parkinson's disease patients to IPX066, modified-release levodopa-carbidopa (NUMIENT™), from other levodopa-carbidopa formulations
Gupta, S.
Rubens, R.
Rustay, N.
Khanna, S.
Kell, S.
EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 526 - 526
[9] Improved adherence to levodopa/carbidopa/entacapone (Stalevo®) or levodopa/carbidopa and entacapone as separate tablets reduces medical care utilization and costs among Parkinson's disease patients
Delea, T.
Thomas, S.
Hagiwara, M.
Stacy, M.
PARKINSONISM & RELATED DISORDERS, 2007, 13 : S100 - S101
[10] Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: Pharmacokinetic and quality-of-life measures
Pahwa, R
Lyons, K
McGuire, D
Silverstein, P
Zwiebel, F
Robischon, M
Koller, WC
MOVEMENT DISORDERS, 1997, 12 (05) : 677 - 681

← 1 2 3 4 5 →